L. Kristin Newby, MD, MHS
Department / Division
Medicine /
Medicine - Cardiology
Address
DUMC 3213
Durham, NC 27710
Appointment Telephone
919-681-5816
Office Telephone
919-668-8805
Fax Telephone
919-668-7056
- MD, Indiana University School of Medicine, 1987
- Internal Medicine, Duke University Medical Center, 1987-1990
- Cardiology, Duke University Medical Center, 1990-1993
- MHS, Clinical Research, Duke University School of Medicine, 2002
Clinical Interests
General noninvasive and critical care cardiology including acute chest pain,
acute and chronic coronary artery disease, heart failure, outpatient
consultative cardiology
Research Interests
Research Description
General Focus: Clinical investigation the process and treatment of acute and chronic coronary artery disease and systems issues for delivery of care to patients with these illnesses. Particular interests include management of patients with chest pain and unstable angina, evaluation of the use of biochemical markers other than CK-MB for diagnosis and risk stratification in these patients, issues related to coronary artery disease in women, and systems issues regarding optimizing the process of delivery of care to patients with acute and chronic coronary artery disease. Finally, I have a strong interest in defining the genetic contribution to development of coronary artery disease.
Key words: coronary artery disease acute myocardial infarction unstable angina chest pain women biochemical markers risk stratification genetics
This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- Amgen, Inc.
- Amylin Pharmaceuticals, Inc.
- AstraZeneca
- Bristol-Myers Squibb
- DiaDexus
- Eli Lilly & Co.
- Elsevier
- GlaxoSmithKline
- Merck Sharpe & Dohme (Merck & Co, USA)
- Regado Biosciences Inc
Representative Publications
Newby LK, Ohman EM, Christenson RH, Moliterno DJ, Harrington RA, White HD, Armstrong PW, Van de Werf F, Pfisterer M, Hasselblad V, Califf RM, Topol EJ; for the PARAGON B Investigators. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: the PARAGON B Troponin T Substudy. Circulation 2001;103:2891-2896.
(2001)
Newby LK, Storrow AW, Gibler WB, Garvey JL, Tucker JF, Kaplan AL, Schreiber DH, Tuttle RH, McNulty SE, Ohman EM. Bedside multimarker testing for risk stratification in chest-pain units: the CHECKMATE Study. Circulation 2001;103:1832-1837.
(2001)
The 2nd SYMPHONY Investigators. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation 2001;103:1727-1733.
(2001)
Newby LK, Eisenstein EL, Califf RM, Thompson TD, Nelson CL, Peterson ED, Armstrong PW, Van de Werf F, White HD, Topol EJ, Mark DB. Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med 2000;342:749-755.
(2000)
The SYMPHONY Investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Lancet 2000;355:337-345.
(2000)
